Rommelag Marks 50 Years of BFS Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rommelag Marks 50 Years of BFS Technology



Rommelag announced its 50th year of supplying blow-fill-seal machinery, with the brand name bottelpack. Rommelag is a member of the Hansen Group headed by CEO Bernd Hansen, with sales companies in Switzerland, Germany, the US, and China.

All bottelpack machines operate using the blow-fill-seal principle (BFS), a single automatic process in which containers are created from thermoplastic granules (blow), contents are inserted (fill) and closed (seal). BFS technology does not require the cleaning and sterilization processes that are used in other kinds of container production, according to Rommelag. Used for the aseptic packaging of sterile liquids, creams, ointments and vaccines, the machines are equipped with additional modules for QA and monitoring. Modules include aseptic systems for automatic cleaning and sterilization of lines that come into contact with products.

Rommelag reports that aseptic packaging by means of bottelpack BFS systems is gaining popularity and plastic materials offer advantages to manufacturers and users of infusion containers and ampoules. The packaging can be made very thin without risk of breaking, is easily collapsible, and is chemically inert.

Source: Rommelag

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here